Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Cytoreductive nephrectomy for RCC

Ziad Bakouny • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab Sunitinib
CARMENA CYTOSHRINK NORDIC-SUN PROBE

Ziad Bakouny, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his analysis of cytoreductive nephrectomy for metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors or targeted therapy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Ziad Bakouny

4:49
Potential prognostic markers in sarcomatoid and rhabdoid RCC
Ziad Bakouny • 13 Feb 2020
2:41
Translational approaches in immunotherapy
Ziad Bakouny • 15 Feb 2020
3:03
Next-gen immuno-oncology therapies in RCC
Ziad Bakouny • 14 Feb 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals